P-1489. Evaluating the public health impact of infant RSV prophylaxis programs in Spain and the UK: results from the ongoing REACH study

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Oliver Martyn, R. Kramer, Karine Mari, Esther Donkers, J. Jasper Deuring, S. D. FAUST
DOI: 10.1093/ofid/ofaf695.1673
Cited by: 0

Abstract

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of infant respiratory infections. The UK has implemented maternal vaccine to prevent RSV in infants from autumn 2024/5 whereas Spain implemented nirsevimab monoclonal antibody treatment in 2023/4 and 2024/5. The REACH study aimed to quantify the reduction in burden amongst infants of RSV-related hospital care across Spain and the United Kingdom (UK).Figure 1Cumulative RSV hospitalizations in infants

Fields of Study & Subjects

Respiratory viral infections research Pediatric health and respiratory diseases Pneumonia and Respiratory Infections

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN